Neoparin Forte (Enoxaparin Sodium)

Enoxaparin sodium, the active ingredient in Neoparin Forte, is a low molecular weight heparin presented as a sterile injectable solution for subcutaneous, intravenous or extracorporeal use. It is employed to prevent and treat venous thromboembolism in patients at risk, including those undergoing surgery or with acute coronary syndromes.

GNH USA supplies Neoparin Forte as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and transplant centres worldwide, adhering to EU quality standards and providing reliable global distribution to healthcare institutions.

Neoparin Forte, a low molecular weight heparin, is used in several thromboembolic disease pathways.

- Deep vein thrombosis (DVT): prevention of clot formation in at‑risk surgical or medical patients. - Pulmonary embolism (PE): treatment of acute embolic events to restore pulmonary circulation. - Post‑operative prophylaxis: reduction of venous thromboembolism risk after orthopedic and general surgery. - Acute coronary syndrome (ACS): adjunct therapy to inhibit further clot propagation in unstable angina or non‑ST elevation myocardial infarction. - Cardiac catheterisation: prevention of procedural thrombosis during invasive coronary procedures.

Enoxaparin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site bruising or erythema - Minor bleeding (e.g., gum or nosebleeds) - Nausea or mild gastrointestinal discomfort - Headache

Serious or Rare Side Effects: - Major hemorrhage (intracranial or gastrointestinal) - Heparin‑induced thrombocytopenia (HIT) - Allergic reactions including anaphylaxis - Spinal or epidural hematoma following neuraxial procedures

When using Neoparin Forte, clinicians should observe several safety considerations.

- Renal impairment: dose adjustment may be required in patients with reduced creatinine clearance. - Pregnancy: category B; benefits must outweigh potential risks. - Surgery or invasive procedures: discontinue before neuraxial anesthesia to lower bleeding risk. - Concomitant anticoagulants or antiplatelet agents: monitor closely for additive bleeding. - Platelet monitoring: check platelet counts regularly to detect HIT. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Enoxaparin can interact with other medicines, altering its anticoagulant effect or increasing bleeding risk.

Major Interactions (Avoid): - Warfarin: combined use markedly raises bleeding risk. - Direct thrombin inhibitors (e.g., dabigatran): additive anticoagulation may cause severe hemorrhage. - Other heparins or LMWHs: concurrent therapy can lead to excessive anticoagulation. - Fibrinolytic agents (e.g., alteplase): heightened risk of major bleeding.

Moderate Interactions (Monitor Closely): - Antiplatelet drugs (e.g., clopidogrel, aspirin): increase minor bleeding tendencies. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate gastrointestinal bleeding. - Selective serotonin reuptake inhibitors (SSRIs): potential for increased bleeding risk.